ISSN 2073–4034
eISSN 2414–9128

Efficacy And Safety Of Dalfaz In Patients With Symptoms Of Benign Prostatic Hyperplasia (seven Years Of Observation)

D.Yu. Pushkar, P.I. Rasner

Efficacy and safety of Dalfaz in patients with symptoms of benign prostatic hyperplasia (seven years of observation)
The results of the study the effectiveness of long-term treatment with ?-adrenoblocker Dalfaz (alfuzosin), which included 41 patients of benign prostatic hyperplasia (BPH), are presented. The study demonstrated the high safety of Dalfaz administration in patients with urination disorders. Dalfaz has received a good mark as a safe and high effective drug for prolonged drug therapy for BPH. The study confirmed the principal possibility of permanent Dalfaz administration in patients with benign prostatic hyperplasia for many years as first-line drugs for medication correction of urination disorders in patients with BPH.

Keywords

benign prostatic hyperplasia
lower urinary tract symptoms
alfa-blockers
alfuzosin
Dalfaz

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.